Comparison Between Closed-Loop Insulin Delivery System (the Artificial Pancreas) and Sensor-Augmented Pump Therapy: A Randomized-Controlled Crossover Trial
| العنوان: | Comparison Between Closed-Loop Insulin Delivery System (the Artificial Pancreas) and Sensor-Augmented Pump Therapy: A Randomized-Controlled Crossover Trial |
|---|---|
| المؤلفون: | Peter G. Jacobs, Anas El-Fathi, Laurent Legault, Marie Raffray, Ahmad Haidar, Virginie Messier, Rémi Rabasa-Lhoret, Joanna Rutkowski, Nikita Gouchie-Provencher |
| المصدر: | Diabetes Technology & Therapeutics |
| بيانات النشر: | Mary Ann Liebert, Inc., publishers, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Pancreas, Artificial, Glucose control, Endocrinology, Diabetes and Metabolism, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Insulin delivery, Randomized-controlled trial, 030209 endocrinology & metabolism, Artificial pancreas, Pharmacology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Insulin Infusion Systems, Randomized controlled trial, law, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Insulin, 030212 general & internal medicine, Closed-loop, Cross-Over Studies, business.industry, Original Articles, medicine.disease, Crossover study, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Treatment Outcome, Sensor-augmented pump therapy, business, Closed loop |
| الوصف: | Objective: Several studies have shown that closed-loop automated insulin delivery (the artificial pancreas) improves glucose control compared with sensor-augmented pump therapy. We aimed to confirm these findings using our automated insulin delivery system based on the iPancreas platform. Research Design and Methods: We conducted a two-center, randomized crossover trial comparing automated insulin delivery with sensor-augmented pump therapy in 36 adults with type 1 diabetes. Each intervention lasted 12 days in outpatient free-living conditions with no remote monitoring. The automated insulin delivery system used a model predictive control algorithm that was a less aggressive version of our earlier dosing algorithm to emphasize safety. The primary outcome was time in the range 3.9–10.0 mmol/L. Results: The automated insulin delivery system was operational 90.2% of the time. Compared with the sensor-augmented pump therapy, automated insulin delivery increased time in range (3.9–10.0 mmol/L) from 61% (interquartile range 53–74) to 69% (60–73; P = 0.006) and increased time in tight target range (3.9–7.8 mmol/L) from 37% (30–49) to 45% (35–51; P = 0.011). Automated insulin delivery also reduced time spent below 3.9 and 3.3 mmol/L from 3.5% (0.8–5.4) to 1.6% (1.1–2.7; P = 0.0021) and from 0.9% (0.2–2.1) to 0.5% (0.2–1.1; P = 0.0122), respectively. Time spent below 2.8 mmol/L was 0.2% (0.0–0.6) with sensor-augmented pump therapy and 0.1% (0.0–0.4; P = 0.155) with automated insulin delivery. Conclusions: Our study confirms findings that automated insulin delivery improves glucose control compared with sensor-augmented pump therapy. ClinicalTrials.gov no. NCT02846831. |
| اللغة: | English |
| تدمد: | 1557-8593 1520-9156 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fddde90c465355e3ed826a157b7858fTest http://europepmc.org/articles/PMC7906861Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7fddde90c465355e3ed826a157b7858f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15578593 15209156 |
|---|